Skip to main content

Table 2 Association between eight SNPs and T2D in Thai population

From: Impact of KCNQ1, CDKN2A/2B, CDKAL1, HHEX, MTNR1B, SLC30A8, TCF7L2, and UBE2E2 on risk of developing type 2 diabetes in Thai population

Gene

SNP (major/minor alleles*)

aRisk allele freq.

bRisk allele freq.

Subject

Genotype frequency, n (%)

Additive model

Dominant model

Recessive model

P unadjusted

OR (95% CI)

P adjusted

OR (95% CI)

P unadjusted

OR (95% CI)

P adjusted

OR (95% CI)

P unadjusted

OR (95% CI)

P adjusted

OR (95% CI)

A/A

A/B

B/B

KCNQ1

rs2237892

(C > T)

0.76

0.71

Patient

285 (57.0)

192 (38.4)

23 (4.6)

0.060

1.74 (0.99–3.07)

0.020

2.02 (1.08–3.79)

0.128

1.53 (0.88–2.66)

0.057

1.83 (0.98–3.42)

0.025

1.36 (1.04–1.78)

0.018

1.43 (1.06–1.92)

Control

254 (50.8)

205 (41.0)

41 (8.2)

CDKN2A/2B

rs10811661

(T > C)

0.68

0.62

Patient

228 (45.6)

220 (44.0)

52 (10.4)

0.100

1.45 (0.93–2.27)

0.044

1.65 (1.01–2.71)

0.227

1.29 (0.85–1.96)

0.105

1.46 (0.92–2.31)

0.077

1.28 (0.97–1.69)

0.066

1.33 (0.98–1.81)

Control

185 (37.0)

248 (49.6)

67 (13.4)

SLC30A8 c

rs13266634

(C > T)

0.59

0.54

Patient

172 (34.4)

242 (48.4)

86 (17.2)

0.040

1.51 (1.01–2.21)

0.006

1.86 (1.19–2.90)

0.309

1.20 (0.84–1.71)

0.191

1.29 (0.87–1.91)

0.008

1.48 (1.11–1.98)

0.0003

1.81 (1.31–2.50)

Control

137 (27.4)

268 (53.6)

95 (19.0)

HHEX

rs1111875

(A > G)

0.33

0.29

Patient

234 (46.8)

200 (40.0)

66 (13.2)

0.039

1.61 (1.02–2.55)

0.082

1.55 (0.94–2.56)

0.260

1.16 (0.89–1.53)

0.367

1.14 (0.85–1.54)

0.044

1.56 (1.01–2.42)

0.087

1.51 (0.94–2.45)

Control

254 (50.8)

201 (40.2)

45 (9.0)

CDKAL1

rs7756992

(A > G)

0.43

0.40

Patient

156 (31.2)

257 (51.4)

87 (17.4)

0.249

1.27 (0.84–1.90)

0.107

1.44 (0.92–2.24)

0.355

1.14 (0.85–1.52)

0.169

1.25 (0.90–1.72)

0.340

1.19 (0.83–1.71)

0.182

1.30 (0.88–1.94)

Control

171 (34.2)

254 (50.8)

75 (15.0)

TCF7L2

rs7903146

(C > T)

0.08

0.04

Patient

429 (85.8)

67 (13.4)

4 (0.0)

NA

NA

0.006

1.80 (1.18–2.76)

0.025

1.70 (1.06–2.72)

NA

NA

Control

456 (91.2)

44 (8.8)

0 (0.0)

MTNR1B

rs1387153

(C > T)

0.44

0.42

Patient

164 (32.7)

232 (46.3)

104 (21.0)

0.113

1.35 (0.93–1.97)

0.120

1.38 (0.91–2.09)

0.618

1.07 (0.80–1.42)

0.757

1.05 (0.76–1.43)

0.058

1.38 (0.98–1.92)

0.047

1.44 (1.01–2.08)

Control

174 (34.8)

231 (46.2)

95 (19.0)

UBE2E2

rs7612463

(C > A)

0.83

0.82

Patient

346 (69.3)

134 (26.6)

20 (4.0)

0.875

0.94 (0.47–1.89)

0.855

0.93 (0.42–2.03)

0.890

0.95 (0.47–1.90)

0.872

0.93 (0.43–2.03)

0.847

0.97 (0.72–1.29)

0.826

0.96 (0.70–1.32)

Control

339 (67.8)

141 (28.2)

20 (4.0)

  1. Abbreviations: SNP single nucleotide polymorphism, T2D type 2 diabetes, Freqfrequency, A/A homo major allele, A/B heterozygote allele, B/B homo minor allele, OR odds ratio, CI confidence interval, NA not applicable (analytical model not applicable due to low frequency)
  2. A p < 0.006 (0.05 divided by 8, the total number of SNPs studied) was regarded as being statistically significant
  3. P-values were calculated for the additive, dominant, and recessive genetic models using logistic regression with/without adjustment for age, gender, and body mass index. The OR and 95% CI of having the risk allele are shown
  4. *Alleles in bold are the risk alleles for T2D identified in previous studies, while underlined alleles indicate the risk alleles for T2D observed in this study
  5. aRisk allele frequency in patients; bRisk allele frequency in controls; cStatistically significant after Bonferroni correction (multiple-testing) with p-value < 0.006
Back to article page

BMC Medical Genetics

ISSN: 1471-2350

Contact us